Joseph J. Villafranca

The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market.

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Tunnell Consulting, Inc. provides technical, organizational and operational consulting services. It provides life sciences technical services, process and organizational excellence services, strategy and supply chain management services. The firm serves in the area of pharmaceutical, government and biotechnology departments. The company was founded in 1962 and is headquartered in King of Prussia, PA.

Part of Bristol Myers Squibb Co., Bristol-Myers Squibb World Wide Medicines Group manufactures pharmaceutical products. The company is based in Lawrenceville, NJ.

Anima Cell Metrology, Inc. engages in the development of novel technologies to monitor protein synthesis in living cells. The company was founded by Zeev Smilansky and is headquartered in Bernardsville, NJ.